Finnland - finnska - Fimea (Suomen lääkevirasto)

pfizer oy pfizer oy - neisseria meningitidis-c oligosaccharide, kurkkumätä konjugaatti - injektioneste, suspensio, esitäytetty ruisku - meningokokkibakteeri c, puhdistettu polysakkaridi antigeeniin konjugoitu

Finnland - finnska - Fimea (Suomen lääkevirasto)

novartis finland oy - moxifloxacin hydrochloride - silmätipat, liuos - 5 mg/ml - moksifloksasiini

Evrópusambandið - finnska - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokokki-infektiot - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. katso kohdat 4. 4 ja 5. 1 tietoa tiettyjen pneumokokki-serotyyppien suojaamisesta. the use of vaxneuvance should be in accordance with official recommendations.